Aadi bioscience announces financial results for the first quarter 2024 and provides corporate update

Fully enrolled registration-intended precision1 trial;  two-thirds interim analysis planned for q3 2024 fyarro® sales of $5.4 million for q1 2024, reflects distributor ordering patterns and fewer commercial patient initiations at the start of the year conference call to be held today at 8:30 am edt los angeles , may 8, 2024 /prnewswire/ -- aadi bioscience, inc. (nasdaq: aadi), a commercial-stage, precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mtor pathway, today announced financial results for the first quarter ended march 31, 2024, and highlighted recent corporate progress. "i'm pleased to announce that precision1 is now fully enrolled across a broad array of tumor types and our promising development plan continues to gain momentum.
AADI Ratings Summary
AADI Quant Ranking